AI Article Synopsis
Article Abstract
Introduction: Adductor spasmodic dysphonia is an extremely disabling voice disorder that negatively impacts a patient's quality of life (QOL). We performed a systematic review to determine if Botulinum Toxin (BT) injections improved voice related QOL in patients with this disorder.
Methods: PubMed, EMBASE, Web of Science, Cochrane Library, ProQuest, and Scopus from 2000, to and including November 1st, 2018, were searched. We identified randomized controlled trials, controlled trials, and observational studies of the effects of BT injections on the QOL in patients with adductor spasmodic dysphonia. The two authors, separately and individually chose the studies based on inclusion criteria, assessed study quality, and relevant extracted data.
Results: Nine studies used the Voice Handicap Index (VHI). The results showed significant changes pre- to post-BT injection (SMD = -0.357; 95% CI: -0.579, -0.136; z = 3.16; P = 0.002; I-squared = 0.000%). Five studies used the Voice-Related QOL; their results also showed a significant improvement pre- to postinjection (SMD = -2.99; 95% CI: -3.27, -1.32; z = 4.61; P < 0.001; I-squared = 87%). Three other studies used other, shortened versions of the VHI, VHI-10. They also showed significant results (SMD = -0.145; 95% CI: -0.349, 0.06; z = 1.38; P = 0.17; I-squared = 0.000).
Conclusion: BT injections positively affect patients' QOL. However, patients' QOL scores may never be normalized, in line with perceptual voice quality and acoustic parameters.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvoice.2019.07.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spasmodic dysphonia: the need for a combined neurological and phoniatric approach.
J Neural Transm (Vienna)
December 2024
IAB - Interdisciplinary Working Group for Movement Disorders, Hamburg, Germany.
Spasmodic dysphonia (SD) is now generally considered to be a task-specific focal dystonia. For the first time, we wanted to explore the relationship between SD and dystonia from a combined neurological and phoniatric perspective. For this, we studied 115 patients with non-psychogenic SD by a combined neurological and phoniatric evaluation.
View Article and Find Full Text PDFCentral Pathology in Spasmodic Dysphonia.
J Voice
December 2024
Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; Department of Otolaryngology Head and Neck Surgery, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. Electronic address:
Introduction: Spasmodic dysphonia a voice disorder characterized by loss of voluntary control of vocal fold movements during speech production. The pathophysiology is not well understood, but there have been proposed connections to areas within the brain such as the reticular formation surrounding the tractus solitarius, spinal trigeminal and ambiguus nuclei, inferior olive, and pyramids.
Objective: To determine whether there are differences on brain Magnetic resonance imaging (MRI) with and without gadolinium in patients affected by spasmodic dysphonia compared with those without to determine whether there is a central process involved in spasmodic dysphonia (SD) pathophysiology.
Myoneurectomy for Adductor Spasmodic Dysphonia: Long-Term Outcomes, Complications, and Recurrence.
Laryngoscope
November 2024
Department of Otorhinolaryngology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
Article Synopsis
- The study aimed to assess the long-term effectiveness and safety of endoscopic myoneurectomy (EMN) of the thyroarytenoid muscle in treating adductor spasmodic dysphonia (AdSD), focusing on vocal outcomes and complications.
- Out of 48 patients treated, 79.2% experienced success, with significant improvements in vocal function reflected in a drop in the Voice Handicap Index score from 97 to 26 post-treatment.
- While some patients faced adverse effects like granulomas and glottic insufficiency, the procedure demonstrated high success rates and minimal complications, highlighting its benefits for vocal improvement.
Transnasal Endoscopic Injection of Botulinum Toxin in Patients with Adductor Spasmodic Dysphonia.
Iran J Otorhinolaryngol
September 2024
Department of Otorhinolaryngology - Head and Neck Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
Introduction: Adductor Spasmodic Dysphonia (ADSD) is the most common form of spasmodic dysphonia. It encompasses various symptoms affecting voice and speech. The objective of this study is to report the management of patients with ADSD using the transnasal endoscopic approach for laryngeal Botulinum Toxin (Botox) injection.
View Article and Find Full Text PDFEffects of an 11-week vibro-tactile stimulation treatment on voice symptoms in laryngeal dystonia.
Front Neurol
May 2024
Department of Speech, Language and Hearing Sciences, University of Minnesota, Minneapolis, MN, United States.
Background: Laryngeal dystonia is a task-specific focal dystonia of laryngeal muscles that impairs speech and voice production. At present, there is no cure for LD. The most common therapeutic option for patients with LD involves Botulinum neurotoxin injections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!